Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
VELETRI Market Size And Revenue Outlook Through 2030
The veletri market has demonstrated strong growth in recent years. It is anticipated to increase from $1.45 billion in 2025 to $1.56 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.7%. This historical growth can be attributed to the clinical effectiveness of epoprostenol, a rise in the diagnosis of PAH, the dependence of hospitals on IV prostacyclins, the restricted availability of oral alternatives, and enhanced PAH survival rates.
The veletri market size is projected to exhibit robust growth in the coming years, with an anticipated increase to $2.07 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.4%. This expansion during the forecast period can be attributed to factors such as a rise in PAH prevalence, the development of more specialty PAH centers, an increasing demand for stable formulations, the wider adoption of infusion therapy, and enhanced awareness of PAH. Key trends observed in this period include the growing acceptance of non-refrigerated prostacyclin therapies, a greater utilization of continuous infusion PAH treatments, a rising need for advanced PAH vasodilators, the expansion of hospital-based PAH management approaches, and an increased focus on improving PAH patient mobility.
Get A Free Sample Report With In-Depth Market Insights:
VELETRI Market Industry Drivers: What’s Behind The Revenue Growth?
The growing occurrence of venous conditions is anticipated to stimulate the expansion of the VELETRI market in the future. These diseases involve compromised blood circulation within veins, resulting in symptoms such as swelling, discomfort, and potential complications like varicose veins and deep vein thrombosis. Key contributors to this rising prevalence include an aging demographic, inactive living habits, increased obesity rates, and advancements in diagnostic methods. VELETRI serves to enhance physical activity tolerance and alleviate symptoms for individuals suffering from venous disorders impacting the pulmonary blood vessels. As an illustration, data from the Centers for Disease Control and Prevention, a US-based government body, indicated that annually, as of January 2025, up to 900,000 individuals in the United States are affected by venous thromboembolism (VTE), a condition involving blood clots, leading to an estimated 60,000 to 100,000 deaths each year. Consequently, the expanding incidence of venous diseases is a significant impetus behind the VELETRI market’s growth.
VELETRI Market Segment Performance And Emerging Opportunities
The veletri market covered in this report is segmented –
1) By Formulation Stability Type: Room-Temperature Stable Formulation, Refrigeration-Required Formulation
2) By Treatment Setting: Hospitals, Specialized Pulmonary Hypertension Centers
3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies
Subsegments:
1) By Room-Temperature Stable Formulation: Ready-to-Use Formulation, Extended Stability Infusion Solution
2) By Refrigeration-Required Formulation: Reconstituted Cold-Chain Formulation, Limited-Stability Infusion Solution
#VELETRI Market Growth Trends: What’s Shaping The Future Outlook?
Leading companies in the Veletri market are focusing on expanding availability through generic formulations, such as the FDA-approved epoprostenol sodium injection, to provide economical treatment options for patients with pulmonary arterial hypertension. Generic Veletri refers to therapeutically equivalent versions of the brand-name epoprostenol product that meet FDA standards for quality, safety, and efficacy, offering the same clinical benefits at a lower cost. For example, in October 2025, Mylan Pharmaceuticals, a US-based pharmaceutical company, received FDA approval for its generic Veletri (epoprostenol sodium) injection. The product is provided in multiple vial strengths, including 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL, and 200 mg/20 mL, and delivers the identical prostacyclin mimetic activity as the branded version, assisting in improving exercise tolerance and managing symptoms in PAH patients.
VELETRI Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the veletri market are Johnson & Johnson, Bayer Pharma AG, Novartis AG, GlaxoSmithKline plc, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz International GmbH, Sun United Therapeutics Corporation, Actelion Pharmaceuticals Ltd., Bayer Pharma AG, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Johnson & Johnson, Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Euroapi S.A., Pfizer CentreOne, Sai Life Sciences Limited, Zhejiang Ausun Pharmaceutical Co. Ltd., Yonsung Fine Chemicals Co. Ltd., Cayman Pharma S.r.o., Nichi-Iko Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Hikma Pharmaceuticals plc
View The Full VELETRI Market Report:
VELETRI Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the VELETRI market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veletri market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
